Advertisement
U.S. markets closed
  • S&P Futures

    5,208.75
    -6.00 (-0.12%)
     
  • Dow Futures

    39,208.00
    -15.00 (-0.04%)
     
  • Nasdaq Futures

    18,189.50
    -42.00 (-0.23%)
     
  • Russell 2000 Futures

    2,048.40
    -1.40 (-0.07%)
     
  • Crude Oil

    82.67
    -0.05 (-0.06%)
     
  • Gold

    2,165.20
    +0.90 (+0.04%)
     
  • Silver

    25.34
    +0.08 (+0.30%)
     
  • EUR/USD

    1.0875
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2726
    -0.0003 (-0.02%)
     
  • USD/JPY

    149.2560
    +0.1580 (+0.11%)
     
  • Bitcoin USD

    66,315.26
    -1,180.07 (-1.75%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,501.79
    -238.65 (-0.60%)
     

Protara Therapeutics to Participate in Upcoming Investor Conferences

Protara Therapeutics
Protara Therapeutics

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:

  • Cowen 43rd Annual Health Care Conference. A fireside chat will take place on Wednesday, March 8, 2023 at 9:50 am ET in Boston, MA.

  • Oppenheimer 33rd Annual Healthcare Conference. A corporate presentation will take place virtually on Tuesday, March 14, 2023 at 1:20 pm ET.

A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836


Advertisement